Euractiv Est. 1min 13-10-2021 (updated: 26-11-2021 ) [SHUTTERSTOCK/JEVTIC] Euractiv is part of the Trust Project >>> Print Email Facebook X LinkedIn WhatsApp Telegram A fairly recent but already fast-growing industry, the biotech sector seeks to claim a role in Europe as a catalyst for growth in the aftermath of the COVID crisis. Technology applied to life science proved to be crucial during the pandemic, but the public health emergency also showed that there are different speeds in Europe when it comes to biotech. Now the European biotech ecosystem wants to assert its contribution not only to a ‘healthier’ but also to a ‘better’ planet, as the potential of the sector ranges from rare diseases to improving our quality of life. In this special piece, EURACTIV takes a dive into the benefits the biotech sector could bring to society as well as bottlenecks in the value chain and risks for the European industry coming from the rise of new global actors. Download PDF Europabio: Life science needs future-proof approach to become innovation ‘powerhouse’ News | Health 13-10-2021 Est. 6minThe EU's policy priorities are a once-in-a-generation change to the regulatory framework offering both the industrial biotech and healthcare sectors an opportunity to set a direction for the next decades, says the newly appointed chairman of EuropaBio.